Leronlimab's data on COVID-19 is simply not yet from a clinical trial. EIND's are by their nature anecdotal. That's why the trials need to enroll ASAP - the FDA can't and won't ignore rock solid data from clinical trials. Heck, they'll RUN with marginally successful data!